5 results

  • ilumya

    (tildrakizumab-asmn)
    Sun Pharmaceutical Industries, Inc.
    ILUMYA® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

  • omvoh

    (mirikizumab-mrkz)
    Eli Lilly and Company
    OMVOH is indicated for treating moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease in adults.

  • skyrizi

    (Risankizumab-rzaa)
    AbbVie Inc.
    SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis in adults.

  • stelara

    (ustekinumab)
    Janssen Biotech, Inc.
    STELARA® is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adult patients.

  • tremfya

    (Guselkumab)
    Janssen Biotech, Inc.
    TREMFYA is indicated for adult patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, specifically those who are candidates for systemic therapy or phototherapy.